Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN
Lisa Licitra(University of Milan), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Carsten Bokemeyer(Universität Hamburg), Stefanie Scheid(Max Planck Society), S. Stoerkel(Universität Hamburg), H. Kienzer(Universität Hamburg), Christopher Stroh(Universität Hamburg), F. Rolland(Institut de Cancérologie de l'Ouest), Éva Remenár(National Institute of Oncology)
Cited by 22
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879